Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|February 23, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-03-01-2017
- Volume 12
- Issue 3
Metrohm USA Announces Winner of Young Chemist Award
Author(s)Pharmaceutical Technology Editors
Metrohm USA presented the Young Chemist Award to Aldin Malkoc for his work on cooperative, DNA-based molecular elements for electrochemical biosensors.
Advertisement
On Feb. 17, 2017, Metrohm USA announced that Aldin Malkoc is the winner of the company’s 2017 Young Chemist Award. Malkoc is completing his graduate work at Arizona State University where he works under the supervision of professor Michael Caplan, chair of the Biomedical Engineering Department, and assistant professor Jeffrey LaBelle.
Malkoc’s research focuses on cooperative, DNA-based molecular elements for electrochemical biosensors. This rapid, point-of-care, low-cost, and highly specific method of genetic mutation detection is a new technology that has the potential to impact healthcare in developing countries and underrepresented clinics where low-cost and rapid treatment are important.
The Young Chemist Award is open to all undergraduate, graduate, post-graduate, and doctorate students residing and studying in the United States and Canada who are performing novel research in the fields of titration, ion chromatography, spectroscopy, and electrochemistry.
Source: Metrohm USA
Articles in this issue
over 9 years ago
Viewpoint: No Clear Path for Pharma or Outsourcingover 9 years ago
Standards Set Excipient GMPs, But Collaboration is Neededover 9 years ago
Monitoring Supply Chain Risk on a Limited Budgetover 9 years ago
Evaluating E&L Studies for Single-Use Systemsover 9 years ago
PfizerCentreOne Expands Fill/Finish Services in Michiganover 9 years ago
Novasep Opens New Bioconjugation Unit in Franceover 9 years ago
Recipharm Completes Kemwell AcquisitionAdvertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
Complying with International Pharmacopoeias
4
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
5